Could new technology save your daily cup of coffee?
Peer-Reviewed Publication
Updates every hour. Last Updated: 26-Jun-2025 11:10 ET (26-Jun-2025 15:10 GMT/UTC)
Realizing the point-of-care tumor markers biodetection with good convenience and high sensitivity possesses great significance for prompting cancer monitoring and screening in biomedical study field. Herein, the quantum dots luminescence and microfluidic biochip with machine vision algorithm-based intelligent biosensing platform have been designed and manufactured for point-of-care tumor markers diagnostics. The employed quantum dots with excellent photoluminescent performance are modified with specific antibody as the optical labeling agents for the designed sandwich structure immunoassay. The corresponding biosensing investigations of the designed biodetection platform illustrate several advantages involving high sensitivity (~ 0.021 ng mL-1), outstanding accessibility, and great integrability. Moreover, related test results of human-sourced artificial saliva samples demonstrate better detection capabilities compared with commercially utilized rapid test strips. Combining these infusive abilities, our elaborate biosensing platform is expected to exhibit potential applications for the future point-of-care tumor markers diagnostic area.
Would you trust a driverless car? A a new study by Australian and French researchers shows that augmented reality (AR) could increase overall confidence in autonomous vehicles by simulating the experience and allowing drivers to personalise the AR interface.
Inspired by advances in cancer therapy, a team at the Buck Institute has engineered immune cells equipped with specialized targeting devices called chimeric antigen receptors (CARs) that can distinguish and respond to tau tangles and various forms of toxic amyloid plaques, both of which are implicated in Alzheimer’s disease pathology. The proof-of-concept study, now online at the Journal of Translational Medicine, holds the promise of being able to precisely deliver therapeutic drugs directly to affected areas of the brain with fewer side effects.
Cambridge researchers urge public health bodies like the NHS to provide trustworthy, research-driven alternatives to platforms driven by profit.